<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Distal esophageal spasm and hypercontractile esophagus
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Distal esophageal spasm and hypercontractile esophagus
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Distal esophageal spasm and hypercontractile esophagus
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ikuo Hirano, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nicholas J Talley, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen M Robson, MD, MBA, FACG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 02, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with esophageal dysmotility may present with dysphagia, noncardiac chest pain, heartburn and/or regurgitation. After inflammatory and structural abnormalities are excluded by performing an upper gastrointestinal endoscopy (esophagogastroduodenoscopy), esophageal manometry is often performed to assess esophageal motor function.
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          Barium
         </a>
         esophagram, videofluoroscopic swallow studies, and esophageal impedance planimetry may complement endoscopic assessment and obviate the need for esophageal manometry in specific instances (ie, oropharyngeal dysphagia, subtle esophageal stricture).
        </p>
        <p>
         This topic will review the pathophysiology, clinical features, diagnosis, and management of the following disorders of esophageal peristalsis: distal esophageal spasm (DES; formerly diffuse esophageal spasm) and hypercontractile (formerly jackhammer) esophagus (HE). Absent esophageal contractility, which may be related to an underlying connective tissue disorder, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7548.html" rel="external">
          "Gastrointestinal manifestations of systemic sclerosis (scleroderma)"
         </a>
         .)
        </p>
        <p>
         The approach to the evaluation of patients with dysphagia is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2241.html" rel="external">
          "Approach to the evaluation of dysphagia in adults"
         </a>
         .)
        </p>
        <p>
         The evaluation of chest pain of esophageal origin is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2262.html" rel="external">
          "Evaluation of the adult with chest pain of esophageal origin"
         </a>
         .)
        </p>
        <p>
         The evaluation of chest pain of nonesophageal origin is also addressed separately. (See
         <a class="medical medical_review" href="/z/d/html/6832.html" rel="external">
          "Outpatient evaluation of the adult with chest pain"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/288.html" rel="external">
          "Evaluation of the adult with chest pain in the emergency department"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CLASSIFICATION BASED ON ESOPHAGEAL MANOMETRY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on high resolution manometry with esophageal pressure topography, esophageal motility disorders are classified according to the Chicago Classification [
         <a href="#rid1">
          1-3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/17125.html" rel="external">
          "High resolution manometry", section on 'Overview'
         </a>
         .)
        </p>
        <p>
         The Chicago Classification categorizes esophageal motility disorders according to the deglutitive pressure (ie, pressure with swallowing) of the esophagogastric junction (EGJ) as measured by the integrated relaxation pressure (IRP). An esophageal manometry study that demonstrates impaired EGJ relaxation (ie, elevated IRP) and absent peristalsis is consistent with a diagnosis of primary or secondary achalasia. The clinical manifestations, diagnosis, and management of achalasia are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2268.html" rel="external">
          "Achalasia: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2261.html" rel="external">
          "Overview of the treatment of achalasia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2245.html" rel="external">
          "Pneumatic dilation and botulinum toxin injection for achalasia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15060.html" rel="external">
          "Surgical myotomy for achalasia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         An elevated IRP in the presence of intact esophageal peristaltic function is consistent with the diagnosis of EGJ outflow obstruction (EGJOO), especially when combined with delayed esophageal emptying on a
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         esophagram or impaired EGJ opening using impedance planimetry.
        </p>
        <p>
         If the IRP is normal, motility disorders are then further categorized based on abnormalities in esophageal peristalsis. The major disorders of esophageal peristalsis are distal esophageal spasm, hypercontractile (jackhammer) esophagus, absent peristalsis, and ineffective esophageal motility. Absent esophageal peristalsis (often related to systemic sclerosis) is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7548.html" rel="external">
          "Gastrointestinal manifestations of systemic sclerosis (scleroderma)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2107334865">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Observational studies using diagnostic criteria from the Chicago Classification suggest that DES and HE are uncommon disorders among patients referred for motility testing [
         <a href="#rid4">
          4-7
         </a>
         ]. In a study of 1070 patients with dysphagia and chest pain who were referred for esophageal manometry, 24 patients (2 percent) had manometric findings suggestive of DES [
         <a href="#rid4">
          4
         </a>
         ]. In two studies including over 900 patients referred for esophageal manometry, the prevalence of HE ranged from 1 to 4 percent [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2107333572">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The underlying pathology of DES and HE are not clearly understood, but theories for the potential mechanisms leading to disease manifestations have been described [
         <a href="#rid8">
          8-16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1340193331">
         <span class="h2">
          Distal esophageal spasm
         </span>
         <span class="headingEndMark">
          —
         </span>
         DES is defined by premature and rapidly propagated contractions in the distal esophagus [
         <a href="#rid8">
          8
         </a>
         ]. Premature and rapid contractions are associated with esophageal bolus retention. Similar to achalasia, DES is classified as a disorder of deglutitive inhibition with dysfunction of nitrinergic (nitric oxide) enteric neural innervation of the smooth muscle portion of the esophagus. This hypothesis is supported by in vitro and in vivo studies that demonstrate simultaneous esophageal contractions with inhibition of nitric oxide synthase [
         <a href="#rid11">
          11,17
         </a>
         ]. Furthermore, in small case series including patients with DES, phosphodiesterase inhibitors (by increasing guanylate cyclase, the second messenger for nitric oxide) [
         <a href="#rid9">
          9
         </a>
         ] and nitrates (as nitric oxide donors) [
         <a href="#rid10">
          10
         </a>
         ] were associated with improving symptoms and esophageal motor function. This is further reinforced by the observation that the normal peristaltic pattern in asymptomatic individuals will change to a spastic pattern during administration of a nitric oxide scavenger, with some individuals experiencing chest pain [
         <a href="#rid11">
          11
         </a>
         ]. Several case reports have described progression from DES to achalasia over time, and these observations support a shared pathophysiology [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Limited studies have demonstrated degeneration of vagal fibers, inflammatory infiltration of the myenteric plexus, hypertrophy of the muscularis propria and variable loss of enteric ganglion cells in the myenteric plexus [
         <a href="#rid19">
          19,20
         </a>
         ].
        </p>
        <p>
         While a cause of enteric neural dysfunction in DES has not been identified, esophageal spasm and dysmotility may also be induced by esophageal acid exposure and chronic opioid use [
         <a href="#rid15">
          15,16,21,22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2630346158">
         <span class="h2">
          Hypercontractile esophagus
         </span>
         <span class="headingEndMark">
          —
         </span>
         The vigorous esophageal contractions seen in patients with HE (or nutcracker esophagus in older studies using conventional manometry) may be due to excessive excitatory enteric neural innervation and/or smooth muscle hypertrophy [
         <a href="#rid12">
          12-14
         </a>
         ].
        </p>
        <p>
         Both mechanical and physiologic obstruction of the EGJ may result in increased amplitudes of esophageal contractions. Thus, HE may be secondary to a mechanical or functional obstruction. Mechanical obstruction can be in the distal esophagus, esophagogastric junction, or proximal stomach (as described in patients with Roux-en-Y gastric bypass or magnetic sphincter augmentation). On the other hand, HE and esophagogastric junction outflow obstruction (EGJOO) may result from loss of deglutitive inhibition. An association between HE, with or without EGJOO, has been identified in patients with chronic opioid use [
         <a href="#rid21">
          21,22
         </a>
         ]. HE has also been identified in some patients with eosinophilic esophagitis (eg, those with muscular involvement) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H2107334765">
         <span class="h2">
          Clinical manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most symptomatic patients with DES or HE present with dysphagia and/or chest pain [
         <a href="#rid7">
          7,24
         </a>
         ]. Patients have esophageal dysphagia, which is characterized by difficulty swallowing and often a sensation of solid food or liquids getting stuck or passing slowly. The dysphagia may localize to the suprasternal notch or chest. Retrosternal, noncardiac chest pain may be the predominant symptom [
         <a href="#rid25">
          25
         </a>
         ]. In some cases, patients have symptoms of heartburn and/or regurgitation, but these symptoms are usually accompanied by either dysphagia and/or noncardiac chest pain.
        </p>
        <p>
         As an example, in a study of 34 patients with HE, 23 patients (67 percent) reported dysphagia and 16 patients (47 percent) had chest pain [
         <a href="#rid24">
          24
         </a>
         ]. Dysphagia was associated with hypercontractile swallows on manometry, while chest pain was not associated with manometric findings. (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         below.)
        </p>
        <p>
         Gastroesophageal reflux disease may coexist with disorders of esophageal peristalsis. In a series of 108 patients with DES, 41 patients (34 percent) had pathologic acid reflux demonstrated by either pH monitoring or endoscopy [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H661049862">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         DES and HE appear differently on imaging:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Distal esophageal spasm
         </strong>
         –
         <strong>
         </strong>
         In patients with DES, simultaneous contractions may result in a "rosary bead" or "corkscrew" appearance of the esophagus on
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         esophagram  (
         <a class="graphic graphic_diagnosticimage graphicRef69821" href="/z/d/graphic/69821.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef93739" href="/z/d/graphic/93739.html" rel="external">
          image 2
         </a>
         ). However, barium esophagram is neither sensitive nor specific for DES. In a study including 76 patients with DES who had a barium esophagram report available for review, 43 patients (57 percent) had nonspecific abnormalities (eg, tertiary contractions resulting in partial lumen obliteration), while only three patients (4 percent) had an esophagus with a corkscrew appearance [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypercontractile esophagus
         </strong>
         –
         <strong>
         </strong>
         In patients with HE,
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         esophagram shows normal sequential peristalsis. However, the esophagram may identify secondary causes of hypercontractility, including a distal mechanical obstruction, hiatal hernia, or extrinsic compression.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2305429680">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis for DES and HE includes other causes of esophageal dysphagia and noncardiac chest pain:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastroesophageal reflux disease (GERD)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Esophageal stricture including Schatzki ring and peptic stricture (see
         <a class="medical medical_review" href="/z/d/html/2264.html" rel="external">
          "Esophageal rings and webs"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eosinophilic esophagitis with muscular involvement
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonreflux esophagitis (eg, infectious, medication-induced, graft-versus-host disease, lichen planus, radiation)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hiatus hernia, especially paraesophageal type (see
         <a class="medical medical_review" href="/z/d/html/2259.html" rel="external">
          "Hiatus hernia"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postoperative anatomy (eg, fundoplication, bariatric surgery) (see
         <a class="medical medical_review" href="/z/d/html/585.html" rel="external">
          "Bariatric operations: Late complications with subacute presentations"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Esophageal diverticula
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Functional gastrointestinal disorder (eg, functional dysphagia, functional chest pain)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Opioid-induced esophageal dysmotility – Opioid-induced esophageal dysmotility is increasingly being reported in case series, and it can mimic primary motility disorders [
         <a href="#rid21">
          21,22
         </a>
         ]. As an example, in an observational study of 4075 patients who underwent esophageal manometry, opioid use was associated with higher rates of a manometric diagnosis of esophageal dysmotility compared with no opioid exposure (DES: 11 versus 5 percent, and HE: 9 versus 3 percent) [
         <a href="#rid22">
          22
         </a>
         ]. In addition, small case series have demonstrated impaired lower esophageal sphincter relaxation after administration of
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Management of opioid-associated esophageal dysmotility is uncertain. While cessation of opioids is optimal, tapering or discontinuing opioids may be challenging. Nevertheless, limited reports have shown improvement in esophageal motor dysfunction with discontinuation of opioids [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/120967.html" rel="external">
          "Opioid tapering for patients with chronic pain"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         Data on the use of opioid receptor antagonists for symptomatic improvement are mixed. For patients with persistent symptoms who are unable to stop opioids, medical therapy or botulinum toxin injection are reasonable options.
        </p>
        <p>
        </p>
        <p>
         Most of these conditions can be excluded by taking a history and by upper gastrointestinal endoscopy with esophageal biopsy, although
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         esophagram can provide complementary information particularly for patients with postoperative anatomy and subtle mechanical strictures. (See
         <a class="medical medical_review" href="/z/d/html/2262.html" rel="external">
          "Evaluation of the adult with chest pain of esophageal origin"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2241.html" rel="external">
          "Approach to the evaluation of dysphagia in adults"
         </a>
         .)
        </p>
        <p>
         Patients with GERD symptoms (heartburn, regurgitation) that are refractory to acid suppressive therapy can be further evaluated with esophageal pH or combined pH-impedance testing. The approach to the diagnosis and treatment of refractory GERD is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2239.html" rel="external">
          "Approach to refractory gastroesophageal reflux disease in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2248.html" rel="external">
          "Esophageal multichannel intraluminal impedance testing", section on 'Combined multichannel intraluminal impedance and pH'
         </a>
         .)
        </p>
        <p>
         Patients with noncardiac chest pain and/or dysphagia with a normal upper endoscopy including esophageal biopsy are often evaluated with esophageal manometry to exclude esophageal motility disorders (eg, achalasia). (See
         <a class="medical medical_review" href="/z/d/html/17125.html" rel="external">
          "High resolution manometry"
         </a>
         and
         <a class="local">
          'Classification based on esophageal manometry'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3199717121">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H628596299">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical diagnosis of DES and HE should be suspected in a patient presenting with suggestive symptoms including esophageal dysphagia or noncardiac chest pain.
        </p>
        <p>
         Our approach to the diagnostic evaluation includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We perform an upper gastrointestinal endoscopy with esophageal biopsy to rule out other esophageal disorders. For selected patients (eg, patients with history of radiation or caustic esophageal injury), we also often obtain a
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         esophagram. (See
         <a class="medical medical_review" href="/z/d/html/2241.html" rel="external">
          "Approach to the evaluation of dysphagia in adults", section on 'Approach to diagnostic testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the above evaluation is negative or nondiagnostic (eg, tertiary contractions only on
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         esophagram), we perform high resolution esophageal manometry to evaluate for an esophageal motility disorder. (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Patients with a normal structural evaluation and normal manometry study may have symptoms related to a functional gastrointestinal disorder (eg, functional dysphagia, functional chest pain), which is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2241.html" rel="external">
          "Approach to the evaluation of dysphagia in adults", section on 'Functional dysphagia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2262.html" rel="external">
          "Evaluation of the adult with chest pain of esophageal origin", section on 'Management'
         </a>
         .)
        </p>
        <p>
         Impedance planimetry is being incorporated into the diagnostic evaluation of dysphagia at some medical centers. Functional lumen imaging probe (FLIP) is an assessment tool that utilizes impedance planimetry to characterize esophageal contractility, and FLIP is being studied for evaluating patients with suspected DES and HE [
         <a href="#rid27">
          27
         </a>
         ]. The use of FLIP is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/132586.html" rel="external">
          "Functional lumen imaging probe (FLIP) for adults with esophageal disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3748357576">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of DES or HE requires the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exclusion of other, more common conditions associated with symptoms of esophageal dysphagia or noncardiac chest pain. For most patients, the initial testing includes a structural evaluation of the esophagus (upper gastrointestinal endoscopy with esophageal biopsies). (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Identification of characteristic abnormalities on esophageal manometry (see
         <a class="medical medical_review" href="/z/d/html/17125.html" rel="external">
          "High resolution manometry"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Distal esophageal spasm
         </strong>
         – DES is characterized by spastic or premature contractions in the distal esophagus  (
         <a class="graphic graphic_figure graphicRef139544" href="/z/d/graphic/139544.html" rel="external">
          figure 1
         </a>
         ). On high resolution manometry (HRM) with esophageal pressure topography (EPT), DES is defined as the occurrence of premature contractions in at least 20 percent of liquid swallows in the setting of normal relaxation of the esophagogastric junction (ie, normal IRP) [
         <a href="#rid3">
          3,28
         </a>
         ]. A premature contraction is one that is simultaneous, usually with a distal latency (ie, time from onset of the upper esophageal sphincter relaxation to the contractile deceleration point) of less than 4.5 seconds in the setting of normal esophageal contractile vigor (distal contractile integral greater than 450 mmHg∙s∙cm). Loss of deglutitive inhibition during multiple rapid swallows may be observed. (See
         <a class="medical medical_review" href="/z/d/html/17125.html" rel="external">
          "High resolution manometry", section on 'Distal esophageal spasm (DES)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17125.html" rel="external">
          "High resolution manometry", section on 'Distal latency (DL)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         While some studies suggest that patients with DES may be further characterized by different phenotypes, no formal classification of DES phenotypes has been validated [
         <a href="#rid29">
          29,30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hypercontractile esophagus
         </strong>
         – After excluding mechanical obstruction of the distal esophagus or esophagogastric junction (EGJ) with initial testing, HE is characterized by high pressure but normally sequential contractions in the smooth muscle esophagus. On HRM with EPT, criteria for HE are at least 20 percent liquid swallows with a distal contractile integral (DCI) &gt;8000 mmHg∙s∙cm in the setting of normal relaxation of the EGJ (normal integrated relaxation pressure)  (
         <a class="graphic graphic_figure graphicRef139544" href="/z/d/graphic/139544.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid3">
          3,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The DCI reflects the overall strength of the distal contraction (ie, amplitude, duration, and length between the proximal and distal troughs) [
         <a href="#rid32">
          32
         </a>
         ]. Several subtypes of HE have been described including single-peaked hypercontraction, multi-peaked hypercontraction (ie, jackhammer esophagus), or hypercontraction of the lower esophageal sphincter following deglutition  (
         <a class="graphic graphic_figure graphicRef139544" href="/z/d/graphic/139544.html" rel="external">
          figure 1
         </a>
         ). The jackhammer subtype of HE is characterized by higher DCI values and greater symptom association [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/17125.html" rel="external">
          "High resolution manometry"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         HE was previously referred to as "nutcracker esophagus" or "spastic nutcracker," based on conventional manometry studies [
         <a href="#rid1">
          1
         </a>
         ]. Technical differences between conventional manometry and high resolution manometry are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2238.html" rel="external">
          "Overview of gastrointestinal motility testing", section on 'Esophageal manometry'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Caution should be used when comparing data on nutcracker esophagus to HE because criteria for HE using the DCI are more specific with less overlap with healthy populations than the amplitude-based criteria used to define nutcracker esophagus (ie, &gt;180 mmHg).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, a clinically relevant diagnosis of DES or HE requires the presence of symptoms of esophageal dysfunction (mostly dysphagia and/or chest pain) in addition to the manometric features [
         <a href="#rid3">
          3
         </a>
         ]
         <strong>
          .
         </strong>
        </p>
        <p>
        </p>
        <p>
         The findings on esophageal manometry may support another diagnosis such as achalasia or absent peristalsis, and these disorders are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2268.html" rel="external">
          "Achalasia: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7548.html" rel="external">
          "Gastrointestinal manifestations of systemic sclerosis (scleroderma)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2798332576">
         <span class="h2">
          Goals and sequence of therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of a range of symptoms, heterogeneity in manometric features, and limited data on natural history and efficacy of therapies, our treatment approach for DES and HE is based on the following principles:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pretreatment evaluation involves excluding other conditions (eg, eosinophilic esophagitis [muscular variant], esophagogastric junction outflow obstruction [EGJOO], type 3 achalasia, opioid-associated dysmotility). (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The goal of therapy is to provide relief of symptom(s) rather than normalization of manometric features.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If gastroesophageal reflux disease (GERD) has not been excluded with pH testing, we typically begin with empiric antisecretory therapy. (See
         <a class="local">
          'Initial measures'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Selection among other therapies is informed by the patient's response to prior therapy, symptom type (eg, dysphagia, chest pain), symptom severity, disease progression, risk of adverse effects, and patient preferences. For most patients, medical therapy or endoscopic therapy (eg, botulinum toxin injection) is associated with symptomatic improvement. For patients with limited symptom burden, observation alone may be appropriate. In such cases, clinical follow-up and repeat radiographic and/or manometric testing is reasonable.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2453121660">
         <span class="h2">
          Initial measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goals of initial therapy are to control symptoms (eg, heartburn, noncardiac chest pain, regurgitation).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Control GERD symptoms
         </strong>
         –
         <strong>
         </strong>
         We begin a proton pump inhibitor (PPI) twice daily, especially if patients also have GERD symptoms  (
         <a class="graphic graphic_table graphicRef89545" href="/z/d/graphic/89545.html" rel="external">
          table 1
         </a>
         ). The use of PPIs for the treatment of GERD is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults", section on 'Proton pump inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who respond to PPI, we continue therapy for three months. We gradually taper PPI therapy for patients who have been on PPI for three months or longer. If symptoms recur with tapering or discontinuing PPI, we restart it. Selection of PPI, duration of therapy, and tapering schedules are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Administration'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with GERD symptoms or chest pain who do not respond to PPI therapy, subsequent management is based on symptoms and ambulatory pH study results. The approach to the evaluation and treatment of patients with refractory GERD is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2239.html" rel="external">
          "Approach to refractory gastroesophageal reflux disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We initially focus on controlling GERD symptoms for the following reasons [
         <a href="#rid33">
          33
         </a>
         ] (see
         <a class="local">
          'Pathophysiology'
         </a>
         above and
         <a class="local">
          'Clinical features'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         DES and HE may coexist with GERD [
         <a href="#rid26">
          26
         </a>
         ]. As an example, in a study of 44 patients with HE by esophageal manometry, 19 patients (43 percent) had GERD-related symptoms [
         <a href="#rid34">
          34
         </a>
         ]. In a small series of patients with DES who were treated with nitrates, clinical improvement was reported only in patients without coexisting GERD [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Esophageal dysmotility may be induced by acid reflux, and thus, treatment of GERD may help alleviate symptoms of esophageal dysmotility [
         <a href="#rid15">
          15,16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Some treatments for esophageal hyperperistalsis (ie, smooth muscle relaxants) may exacerbate GERD symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial therapy to relax smooth muscle
         </strong>
         – For mildly symptomatic patients, we typically begin a trial of peppermint oil (two Altoids mints taken sublingually before each meal as needed). We use peppermint oil as initial therapy because it is generally well tolerated with minimal or no side effects and because smooth muscle relaxants can relieve symptoms in patients with hypercontractile esophageal peristalsis [
         <a href="#rid36">
          36-38
         </a>
         ]. Peppermint oil improved manometric abnormalities in a case series of eight patients with DES [
         <a href="#rid36">
          36
         </a>
         ]. Two patients also had improvement in chest pain.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2423897645">
         <span class="h2">
          Therapy for persistent symptoms
         </span>
        </p>
        <p class="headingAnchor" id="H381062052">
         <span class="h3">
          Pharmacologic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with persistent symptoms despite initial measures, we use pharmacologic therapy such as an antispasmodic or antihypertensive agent:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antispasmodic agents
         </strong>
         – We use an antispasmodic agent (eg,
         <a class="drug drug_general" data-topicid="8545" href="/z/d/drug information/8545.html" rel="external">
          hyoscyamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9350" href="/z/d/drug information/9350.html" rel="external">
          dicyclomine
         </a>
         ) based on clinical experience and limited published data [
         <a href="#rid39">
          39,40
         </a>
         ]. As an example, hyoscyamine 0.25 mg, orally, three times daily as needed was associated with reduced esophageal contractility and lower esophageal sphincter (LES) pressure [
         <a href="#rid39">
          39
         </a>
         ]. Dicyclomine 20 mg, four times daily as needed, modestly reduced esophageal contractile amplitudes in heathy individuals [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antihypertensive agents
         </strong>
         – We typically use a short-acting nitrate (ie,
         <a class="drug drug_general" data-topicid="8580" href="/z/d/drug information/8580.html" rel="external">
          isosorbide dinitrate
         </a>
         5 to 10 mg, orally, twice or three times daily), although a calcium channel blocker is a reasonable alternative. For nitrate therapy, we begin with a lower dose (eg, isosorbide dinitrate 5 mg twice daily as needed) and caution patients about possible side effects (eg, headache). If the dose is well tolerated, it can be gradually titrated to achieve symptom response. (See
         <a class="medical medical_review" href="/z/d/html/1549.html" rel="external">
          "Nitrates in the management of chronic coronary syndrome", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although data to support the efficacy of antihypertensive agents for relaxing esophageal smooth muscle are limited, indirect data from studies in patients with achalasia suggested that nitrates provided greater reduction in esophageal contractile amplitudes compared with calcium channel blockers [
         <a href="#rid41">
          41
         </a>
         ]. In addition, in two small trials including patients with DES, nitrate therapy was associated with greater symptom improvement compared with calcium channel blockers [
         <a href="#rid10">
          10,35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We infrequently use calcium channel blockers for treating esophageal hypercontractility because adverse effects generally limit their use. Adverse effects related to calcium channel blockers include headache, lightheadedness, hypotension, and constipation. However, extended-release formulations of calcium channel blockers may be better tolerated by some patients because of lower risk of adverse effects than the immediate-release formulations. (See
         <a class="medical medical_review" href="/z/d/html/3832.html" rel="external">
          "Major side effects and safety of calcium channel blockers"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Data supporting the use of calcium channel blockers are mixed, and some studies included patients with nutcracker esophagus rather than HE [
         <a href="#rid37">
          37,38,42
         </a>
         ]. In a trial of 22 patients with nutcracker esophagus, patients treated with
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         (60 to 90 mg four times daily) had greater relief of chest pain compared with placebo [
         <a href="#rid37">
          37
         </a>
         ]. However, in another small trial,
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         showed improvement in esophageal contractile amplitudes but no significant difference in symptoms [
         <a href="#rid42">
          42
         </a>
         ]. In a study evaluating calcium channel blockers in healthy individuals, nifedipine was associated with greater improvement in esophageal contractile pressure compared with
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         or diltiazem, both of which had negligible effects [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tricyclic antidepressants
         </strong>
         — For patients with predominantly chest pain symptoms who cannot tolerate or do not have symptomatic improvement with initial measures and initial pharmacologic therapy, we begin a low-dose tricyclic antidepressant (TCA). The initial dose should be adjusted based upon tolerance and response. Due to the delayed onset of action of antidepressants, three to four weeks of therapy should be attempted before increasing the dose. We typically use either
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          nortriptyline
         </a>
         or
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         with an initial dose of 10 to 25 mg daily at bedtime. We discuss potential adverse effects with the patient (ie, orthostatic hypotension, constipation, dry mouth, blurred vision, urinary retention). (See
         <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">
          "Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects", section on 'Side effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We instruct patients to take the TCA as prescribed rather than on an as-needed basis and to expect that response may not occur until four or more weeks have elapsed. If the TCA is well tolerated, we reassess the patient's symptoms after three months of treatment. If symptoms are improved, treatment is continued for 6 to 12 months, followed by a drug taper, which generally takes two to four weeks to avoid discontinuation symptoms (eg, agitation, anxiety, headache). The approach to discontinuing TCAs is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/105323.html" rel="external">
          "Discontinuing antidepressant medications in adults", section on 'Tricyclics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         TCAs have been shown to be effective in a small randomized trial for relief of chest pain in patients with esophageal motility abnormalities [
         <a href="#rid43">
          43
         </a>
         ]. These results are likely due to the effect on visceral sensory perception as TCAs have not been demonstrated to improve dysmotility [
         <a href="#rid29">
          29
         </a>
         ]. Older studies using conventional manometry suggest that visceral hypersensitivity may be a factor for some patients whose symptoms do not necessarily correlate with manometric abnormalities [
         <a href="#rid44">
          44,45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other pharmacologic options
         </strong>
         — Other antidepressant therapies that alter visceral pain perception can be used for hypercontractile esophageal motility disorders. Low-dose
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         (eg, 25 to 50 mg at bedtime) and serotonin reuptake inhibitors (eg,
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         20 mg daily) can lower esophageal sensitivity, which results in symptomatic relief [
         <a href="#rid46">
          46-51
         </a>
         ].
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          Venlafaxine
         </a>
         may also be an option based on limited evidence [
         <a href="#rid50">
          50,51
         </a>
         ]. However, we do not typically use
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         or
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         because studies have not established their efficacy for treating esophageal dysmotility. (See
         <a class="medical medical_review" href="/z/d/html/2262.html" rel="external">
          "Evaluation of the adult with chest pain of esophageal origin", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Phosphodiesterase inhibitors have been studied for treating esophageal motor disorders and as an alternative for patients who have not responded to other pharmacologic agents [
         <a href="#rid52">
          52-54
         </a>
         ]. In an observational study of 11 patients with hypercontractile esophageal motility disorders,
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         was associated with manometric improvement in nine patients (81 percent) and symptom improvement in four patients (36 percent) [
         <a href="#rid52">
          52
         </a>
         ]. However, two of four patients with symptom improvement discontinued treatment because of adverse side effects. Adverse effects associated with phosphodiesterase inhibitors are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7469.html" rel="external">
          "Treatment of male sexual dysfunction", section on 'Initial therapy: PDE5 inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3876021577">
         <span class="h3">
          Endoscopy-guided botulinum toxin injection
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with DES or HE and persistent symptoms that do not improve with initial measures or subsequent drug therapy, endoscopic therapy with botulinum toxin injection may provide symptom relief and improvement in manometric features [
         <a href="#rid55">
          55-58
         </a>
         ]. (See
         <a class="local">
          'Pharmacologic therapy'
         </a>
         above.)
        </p>
        <p>
         The dose and endoscopic delivery method for botulinum toxin is similar to use of botulinum toxin injection for achalasia, but the injection sites target the distal esophagus. The technique for botulinum toxin injection is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2245.html" rel="external">
          "Pneumatic dilation and botulinum toxin injection for achalasia", section on 'Botulinum toxin injection'
         </a>
         .)
        </p>
        <p>
         Botulinum toxin injection typically provides short-term symptom relief (ie, approximately six months), while the risk of adverse effects is low. Evidence supporting use of botulinum toxin for DES and HE are limited by both heterogeneity in patient populations and small sample sizes [
         <a href="#rid55">
          55-59
         </a>
         ]. In a trial including 22 patients with DES or nutcracker/jackhammer esophagus, botulinum toxin (injected endoscopically at 2 and 7 cm above the EGJ) resulted in greater improvement in dysphagia compared with
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         injection [
         <a href="#rid58">
          58
         </a>
         ]. However, there was no significant improvement in chest pain, regurgitation, or heartburn. Botulinum toxin also resulted in lower LES pressure, but there was no change in simultaneous or repetitive contractions or in contraction duration. In another trial including 23 patients with DES, HE, or type 3 achalasia, there were no significant differences in symptomatic improvement or contractile vigor following botulinum toxin therapy compared with a sham procedure [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1612237111">
         <span class="h3">
          Myotomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We reserve endoscopic and surgical myotomy for selected patients (eg, patients with complications of dysmotility such as impaired esophageal transit or symptomatic epiphrenic diverticula, patients with symptomatic improvement with botulinum toxin). The reported success of myotomy in observational studies is limited by the lack of randomized trials as well as possible inclusion of patients with EGJOO or type 3 achalasia. Evidence of coexisting EGJOO on manometry, impedance planimetry, and/or delayed transit on
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         esophagram may support the use of more invasive interventions [
         <a href="#rid60">
          60
         </a>
         ]. Randomized trials using well-defined, consensus-based outcome measures with long-term follow-up are needed before myotomy is routinely used for DES or HE, which both typically have a benign course. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H637922574">
         <span class="h4">
          Peroral endoscopic myotomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Peroral endoscopic myotomy (POEM) has been associated with symptomatic improvement in patients with hypercontractile esophageal motility disorders [
         <a href="#rid61">
          61-64
         </a>
         ]. In a meta-analysis including 18 patients with DES and 37 patients with HE who underwent POEM, the reported clinical success rates were 88 and 72 percent, respectively, but the definition of clinical improvement varied among studies [
         <a href="#rid61">
          61
         </a>
         ]. In a study including 25 patients with spastic motility disorders who underwent POEM, clinical success was achieved in 85 percent of patients after median follow-up of nine months, and manometric abnormalities resolved in 90 percent of patients [
         <a href="#rid62">
          62
         </a>
         ]. The efficacy and safety of POEM, including adverse events such as symptomatic GERD are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/103958.html" rel="external">
          "Peroral endoscopic myotomy (POEM)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1666816054">
         <span class="h4">
          Surgical myotomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data from small case series and case reports have suggested that laparoscopic surgical myotomy was effective for treating DES and HE [
         <a href="#rid65">
          65,66
         </a>
         ]. In a study of 20 patients with DES, extended surgical myotomy was associated with improvement in dysphagia in 18 patients (90 percent) and chest pain in all patients (100 percent) after median follow-up of 50 months [
         <a href="#rid65">
          65
         </a>
         ]. However, technical limitations related to performing a laparoscopic long myotomy likely accounts for the greater use of POEM for patients with spastic esophageal motility disorders. (See
         <a class="medical medical_review" href="/z/d/html/15060.html" rel="external">
          "Surgical myotomy for achalasia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10098002">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data on the natural history of DES and HE are limited, although observational studies describe a benign clinical course in most patients. There have been no reports of increased risk of mortality or esophageal carcinoma.
        </p>
        <p>
         Data from small case series suggested that spastic esophageal disorders were associated with esophageal diverticula and with progression to achalasia. In a series of 19 patients with esophageal diverticula who had esophageal manometry, six patients (32 percent) had at least one hypercontractile swallow, two patients (11 percent) had jackhammer esophagus, and one patient (5 percent) had DES [
         <a href="#rid67">
          67
         </a>
         ]. In a series of 12 patients with HE, three patients (25 percent) progressed to type 3 achalasia over a mean follow-up of 24 months [
         <a href="#rid68">
          68
         </a>
         ]. In a series of 32 patients with DES, repeat manometry after a mean of 4.8 years demonstrated persistent DES in seven patients, achalasia in one patient, and normal motility in three patients [
         <a href="#rid69">
          69
         </a>
         ]. These findings support evaluating patients for impaired deglutitive esophagogastric junction relaxation during the initial presentation and longitudinal follow-up. (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H548728832">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118129.html" rel="external">
          "Society guideline links: Dysphagia"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/118166.html" rel="external">
          "Society guideline links: Esophageal manometry and pH testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Background
         </strong>
         – Major disorders of esophageal peristalsis include distal esophageal spasm (DES), hypercontractile esophagus (HE), absent esophageal peristalsis, and ineffective esophageal motility. (See
         <a class="local">
          'Classification based on esophageal manometry'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/17125.html" rel="external">
          "High resolution manometry"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology
         </strong>
         – Although the pathophysiology of hypercontractile esophageal motility is not well understood, DES is thought to be a consequence of impaired inhibitory innervation, leading to premature and rapidly propagated contractions in the distal esophagus. Esophageal hyperperistalsis may also be induced by esophageal acid exposure. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Dysphagia and chest pain are the most common symptoms of DES and HE. Some patients also have symptoms of heartburn or regurgitation. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of DES or HE requires the following (see
         <a class="local">
          'Diagnosis'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Exclusion of other conditions associated with symptoms of esophageal dysphagia or noncardiac chest pain. For most patients, the initial testing includes a structural evaluation of the esophagus (upper gastrointestinal endoscopy with esophageal biopsies).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Identification of characteristic abnormalities on esophageal manometry  (
         <a class="graphic graphic_figure graphicRef139544" href="/z/d/graphic/139544.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/17125.html" rel="external">
          "High resolution manometry"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with manometric criteria consistent with DES or HE, we exclude secondary causes of esophageal dysmotility including opioid-induced dysmotility, eosinophilic esophagitis, and impaired esophagogastric junction opening (esophagogastric junction outflow obstruction or mechanical obstruction).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – The goal of initial therapy is to control gastroesophageal reflux disease (GERD) symptoms. For patients with DES or HE and who have GERD symptoms, we suggest initiating proton pump inhibitor (PPI) therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The PPI is typically started with a standard dose taken twice daily  (
         <a class="graphic graphic_table graphicRef89545" href="/z/d/graphic/89545.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who have either no GERD or well-controlled GERD, we suggest a trial of pharmacologic therapy to relax smooth muscle (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Treatment options include an antispasmodic agent (eg,
         <a class="drug drug_general" data-topicid="8545" href="/z/d/drug information/8545.html" rel="external">
          hyoscyamine
         </a>
         0.25 mg three times daily as needed), a nitrate (eg,
         <a class="drug drug_general" data-topicid="8580" href="/z/d/drug information/8580.html" rel="external">
          isosorbide dinitrate
         </a>
         5 to 10 mg twice to three times daily as needed), a calcium channel blocker (eg,
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         , extended release, 30 mg daily), or phosphodiesterase inhibitor (
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         25 to 50 mg daily).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If therapy to relax esophageal smooth muscle is not effective or is not well tolerated, we begin a low-dose tricyclic antidepressant (eg,
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          nortriptyline
         </a>
         10 to 25 mg at bedtime), especially for patients with pain-predominant symptoms. (See
         <a class="local">
          'Therapy for persistent symptoms'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">
          "Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who do not have symptom relief or who do not tolerate pharmacologic therapy, endoscopy-guided botulinum toxin injection into the distal esophagus is a subsequent therapeutic option. (See
         <a class="local">
          'Endoscopy-guided botulinum toxin injection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For selected patients (eg, those with complications of esophageal dysmotility), myotomy (ie, peroral endoscopic myotomy or surgical myotomy) is an alternative intervention because data suggest that myotomy was associated with improvement in symptoms and manometric features. (See
         <a class="local">
          'Myotomy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/103958.html" rel="external">
          "Peroral endoscopic myotomy (POEM)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – The prognosis for patients with DES or HE is favorable. There have been no reports of increased risk of mortality or esophageal carcinoma in patients with these disorders. Progression to achalasia and an association with esophageal diverticula have been reported in a subset of patients. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kahrilas PJ. Esophageal motor disorders in terms of high-resolution esophageal pressure topography: what has changed? Am J Gastroenterol 2010; 105:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pandolfino JE, Ghosh SK, Rice J, et al. Classifying esophageal motility by pressure topography characteristics: a study of 400 patients and 75 controls. Am J Gastroenterol 2008; 103:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yadlapati R, Kahrilas PJ, Fox MR, et al. Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0©. Neurogastroenterol Motil 2021; 33:e14058.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pandolfino JE, Roman S, Carlson D, et al. Distal esophageal spasm in high-resolution esophageal pressure topography: defining clinical phenotypes. Gastroenterology 2011; 141:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roman S, Pandolfino JE, Chen J, et al. Phenotypes and clinical context of hypercontractility in high-resolution esophageal pressure topography (EPT). Am J Gastroenterol 2012; 107:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jia Y, Arenas J, Hejazi RA, et al. Frequency of Jackhammer Esophagus as the Extreme Phenotypes of Esophageal Hypercontractility Based on the New Chicago Classification. J Clin Gastroenterol 2016; 50:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martín-Domínguez V, Pérez-Fernández MT, Marinero A, et al. Hypercontractile esophagus: Clinical context and motors findings in high resolution manometry. Rev Esp Enferm Dig 2015; 107:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rohof WOA, Bredenoord AJ. Chicago Classification of Esophageal Motility Disorders: Lessons Learned. Curr Gastroenterol Rep 2017; 19:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrawal A, Tutuian R, Hila A, Castell DO. Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report. Dig Dis Sci 2005; 50:2059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konturek JW, Gillessen A, Domschke W. Diffuse esophageal spasm: a malfunction that involves nitric oxide? Scand J Gastroenterol 1995; 30:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray JA, Ledlow A, Launspach J, et al. The effects of recombinant human hemoglobin on esophageal motor functions in humans. Gastroenterology 1995; 109:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung HY, Puckett JL, Bhalla V, et al. Asynchrony between the circular and the longitudinal muscle contraction in patients with nutcracker esophagus. Gastroenterology 2005; 128:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korsapati H, Bhargava V, Mittal RK. Reversal of asynchrony between circular and longitudinal muscle contraction in nutcracker esophagus by atropine. Gastroenterology 2008; 135:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dogan I, Puckett JL, Padda BS, Mittal RK. Prevalence of increased esophageal muscle thickness in patients with esophageal symptoms. Am J Gastroenterol 2007; 102:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pehlivanov N, Liu J, Mittal RK. Sustained esophageal contraction: a motor correlate of heartburn symptom. Am J Physiol Gastrointest Liver Physiol 2001; 281:G743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crozier RE, Glick ME, Gibb SP, et al. Acid-provoked esophageal spasm as a cause of noncardiac chest pain. Am J Gastroenterol 1991; 86:1576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamato S, Spechler SJ, Goyal RK. Role of nitric oxide in esophageal peristalsis in the opossum. Gastroenterology 1992; 103:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fontes LH, Herbella FA, Rodriguez TN, et al. Progression of diffuse esophageal spasm to achalasia: incidence and predictive factors. Dis Esophagus 2013; 26:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krishnan K, Lin CY, Keswani R, et al. Endoscopic ultrasound as an adjunctive evaluation in patients with esophageal motor disorders subtyped by high-resolution manometry. Neurogastroenterol Motil 2014; 26:1172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roman S, Kahrilas PJ. Distal esophageal spasm. Curr Opin Gastroenterol 2015; 31:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel D, Callaway J, Vaezi M. Opioid-Induced Foregut Dysfunction. Am J Gastroenterol 2019; 114:1716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel DA, Goss J, Hayat M, et al. Opioid Exposure Differentially Impacts Esophageal Body Contraction Over the Lower Esophageal Sphincter. Gastroenterology 2022; 163:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirano I. Clinical relevance of esophageal subepithelial activity in eosinophilic esophagitis. J Gastroenterol 2020; 55:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herregods TV, Smout AJ, Ooi JL, et al. Jackhammer esophagus: Observations on a European cohort. Neurogastroenterol Motil 2017; 29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akinsiku O, Yamasaki T, Brunner S, et al. High resolution vs conventional esophageal manometry in the assessment of esophageal motor disorders in patients with non-cardiac chest pain. Neurogastroenterol Motil 2018; 30:e13282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almansa C, Heckman MG, DeVault KR, et al. Esophageal spasm: demographic, clinical, radiographic, and manometric features in 108 patients. Dis Esophagus 2012; 25:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlson DA, Baumann AJ, Prescott JE, et al. Validation of secondary peristalsis classification using FLIP panometry in 741 subjects undergoing manometry. Neurogastroenterol Motil 2022; 34:e14192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015; 27:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tutuian R, Mainie I, Agrawal A, et al. Symptom and function heterogenicity among patients with distal esophageal spasm: studies using combined impedance-manometry. Am J Gastroenterol 2006; 101:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Schepper HU, Ponds FA, Oors JM, et al. Distal esophageal spasm and the Chicago classification: is timing everything? Neurogastroenterol Motil 2016; 28:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen JW, Savarino E, Smout A, et al. Chicago Classification Update (v4.0): Technical review on diagnostic criteria for hypercontractile esophagus. Neurogastroenterol Motil 2021; 33:e14115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roman S, Tutuian R. Esophageal hypertensive peristaltic disorders. Neurogastroenterol Motil 2012; 24 Suppl 1:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham DY, Tansel A. Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency. Clin Gastroenterol Hepatol 2018; 16:800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mallet AL, Ropert A, Bouguen G, et al. Prevalence and characteristics of acid gastro-oesophageal reflux disease in Jackhammer oesophagus. Dig Liver Dis 2016; 48:1136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swamy N. Esophageal spasm: clinical and manometric response to nitroglycerine and long acting nitrites. Gastroenterology 1977; 72:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pimentel M, Bonorris GG, Chow EJ, Lin HC. Peppermint oil improves the manometric findings in diffuse esophageal spasm. J Clin Gastroenterol 2001; 33:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cattau EL Jr, Castell DO, Johnson DA, et al. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol 1991; 86:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drenth JP, Bos LP, Engels LG. Efficacy of diltiazem in the treatment of diffuse oesophageal spasm. Aliment Pharmacol Ther 1990; 4:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen M, Mellow M, Robinson MG, Orr WC. Comparison of calcium channel blocking agents and an anticholinergic agent on oesophageal function. Aliment Pharmacol Ther 1987; 1:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koerselman J, Pursnani KG, Peghini P, et al. Different effects of an oral anticholinergic drug on gastroesophageal reflux in upright and supine position in normal, ambulant subjects: a pilot study. Am J Gastroenterol 1999; 94:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gelfond M, Rozen P, Gilat T. Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation. Gastroenterology 1982; 83:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richter JE, Dalton CB, Bradley LA, Castell DO. Oral nifedipine in the treatment of noncardiac chest pain in patients with the nutcracker esophagus. Gastroenterology 1987; 93:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cannon RO 3rd, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994; 330:1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrawal A, Hila A, Tutuian R, et al. Clinical relevance of the nutcracker esophagus: suggested revision of criteria for diagnosis. J Clin Gastroenterol 2006; 40:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mujica VR, Mudipalli RS, Rao SS. Pathophysiology of chest pain in patients with nutcracker esophagus. Am J Gastroenterol 2001; 96:1371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clouse RE, Lustman PJ, Eckert TC, et al. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 1987; 92:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Handa M, Mine K, Yamamoto H, et al. Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach. J Clin Gastroenterol 1999; 28:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broekaert D, Fischler B, Sifrim D, et al. Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2006; 23:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drossman DA, Tack J, Ford AC, et al. Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. Gastroenterology 2018; 154:1140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen TM, Eslick GD. Systematic review: the treatment of noncardiac chest pain with antidepressants. Aliment Pharmacol Ther 2012; 35:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atluri DK, Chandar AK, Fass R, Falck-Ytter Y. Systematic review with meta-analysis: selective serotonin reuptake inhibitors for noncardiac chest pain. Aliment Pharmacol Ther 2015; 41:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eherer AJ, Schwetz I, Hammer HF, et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut 2002; 50:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bortolotti M, Mari C, Lopilato C, et al. Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. Gastroenterology 2000; 118:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox M, Sweis R, Wong T, Anggiansah A. Sildenafil relieves symptoms and normalizes motility in patients with oesophageal spasm: a report of two cases. Neurogastroenterol Motil 2007; 19:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Storr M, Allescher HD, Rösch T, et al. Treatment of symptomatic diffuse esophageal spasm by endoscopic injections of botulinum toxin: a prospective study with long-term follow-up. Gastrointest Endosc 2001; 54:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller LS, Pullela SV, Parkman HP, et al. Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction. Am J Gastroenterol 2002; 97:1640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marjoux S, Brochard C, Roman S, et al. Botulinum toxin injection for hypercontractile or spastic esophageal motility disorders: may high-resolution manometry help to select cases? Dis Esophagus 2015; 28:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanuytsel T, Bisschops R, Farré R, et al. Botulinum toxin reduces Dysphagia in patients with nonachalasia primary esophageal motility disorders. Clin Gastroenterol Hepatol 2013; 11:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mion F, Marjoux S, Subtil F, et al. Botulinum toxin for the treatment of hypercontractile esophagus: Results of a double-blind randomized sham-controlled study. Neurogastroenterol Motil 2019; 31:e13587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel DA, Yadlapati R, Vaezi MF. Esophageal Motility Disorders: Current Approach to Diagnostics and Therapeutics. Gastroenterology 2022; 162:1617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan MA, Kumbhari V, Ngamruengphong S, et al. Is POEM the Answer for Management of Spastic Esophageal Disorders? A Systematic Review and Meta-Analysis. Dig Dis Sci 2017; 62:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khashab MA, Familiari P, Draganov PV, et al. Peroral endoscopic myotomy is effective and safe in non-achalasia esophageal motility disorders: an international multicenter study. Endosc Int Open 2018; 6:E1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nabi Z, Chavan R, Ramchandani M, et al. Long-term Outcomes of Per-oral Endoscopic Myotomy in Spastic Esophageal Motility Disorders: A Large, Single-Center Study. J Clin Gastroenterol 2021; 55:594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chandan S, Mohan BP, Chandan OC, et al. Clinical efficacy of per-oral endoscopic myotomy (POEM) for spastic esophageal disorders: a systematic review and meta-analysis. Surg Endosc 2020; 34:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leconte M, Douard R, Gaudric M, et al. Functional results after extended myotomy for diffuse oesophageal spasm. Br J Surg 2007; 94:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hosaka H, Kawami N, Manabe N, et al. Clinical presentation and therapeutic outcome of patients with jackhammer esophagus-a multicenter cohort study in Japan. Esophagus 2022; 19:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlson DA, Gluskin AB, Mogni B, et al. Esophageal diverticula are associated with propagating peristalsis: a study utilizing high-resolution manometry. Neurogastroenterol Motil 2016; 28:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang L, Pimentel M, Rezaie A. Do Jackhammer contractions lead to achalasia? A longitudinal study. Neurogastroenterol Motil 2017; 29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khatami SS, Khandwala F, Shay SS, Vaezi MF. Does diffuse esophageal spasm progress to achalasia? A prospective cohort study. Dig Dis Sci 2005; 50:1605.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2256 Version 32.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20179690" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Esophageal motor disorders in terms of high-resolution esophageal pressure topography: what has changed?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17900331" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Classifying esophageal motility by pressure topography characteristics: a study of 400 patients and 75 controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33373111" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0©.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21679709" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Distal esophageal spasm in high-resolution esophageal pressure topography: defining clinical phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21931377" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Phenotypes and clinical context of hypercontractility in high-resolution esophageal pressure topography (EPT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26927491" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Frequency of Jackhammer Esophagus as the Extreme Phenotypes of Esophageal Hypercontractility Based on the New Chicago Classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25952802" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Hypercontractile esophagus: Clinical context and motors findings in high resolution manometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28730503" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Chicago Classification of Esophageal Motility Disorders: Lessons Learned.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16240215" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8578161" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Diffuse esophageal spasm: a malfunction that involves nitric oxide?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7557091" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The effects of recombinant human hemoglobin on esophageal motor functions in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15887102" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Asynchrony between the circular and the longitudinal muscle contraction in patients with nutcracker esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18675815" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Reversal of asynchrony between circular and longitudinal muscle contraction in nutcracker esophagus by atropine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17266691" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Prevalence of increased esophageal muscle thickness in patients with esophageal symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11518687" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Sustained esophageal contraction: a motor correlate of heartburn symptom.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1951232" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Acid-provoked esophageal spasm as a cause of noncardiac chest pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1612326" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Role of nitric oxide in esophageal peristalsis in the opossum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22816880" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Progression of diffuse esophageal spasm to achalasia: incidence and predictive factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25041229" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Endoscopic ultrasound as an adjunctive evaluation in patients with esophageal motor disorders subtyped by high-resolution manometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26039725" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Distal esophageal spasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31464739" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Opioid-Induced Foregut Dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35537552" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Opioid Exposure Differentially Impacts Esophageal Body Contraction Over the Lower Esophageal Sphincter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31515617" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Clinical relevance of esophageal subepithelial activity in eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27753176" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Jackhammer esophagus: Observations on a European cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29286206" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : High resolution vs conventional esophageal manometry in the assessment of esophageal motor disorders in patients with non-cardiac chest pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21951821" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Esophageal spasm: demographic, clinical, radiographic, and manometric features in 108 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34120383" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Validation of secondary peristalsis classification using FLIP panometry in 741 subjects undergoing manometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25469569" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The Chicago Classification of esophageal motility disorders, v3.0.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16542281" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Symptom and function heterogenicity among patients with distal esophageal spasm: studies using combined impedance-manometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26553751" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Distal esophageal spasm and the Chicago classification: is timing everything?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33729642" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Chicago Classification Update (v4.0): Technical review on diagnostic criteria for hypercontractile esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22248106" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Esophageal hypertensive peristaltic disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28964908" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27453169" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Prevalence and characteristics of acid gastro-oesophageal reflux disease in Jackhammer oesophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/401445" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Esophageal spasm: clinical and manometric response to nitroglycerine and long acting nitrites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11418786" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Peppermint oil improves the manometric findings in diffuse esophageal spasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1998307" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Diltiazem therapy for symptoms associated with nutcracker esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2103759" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Efficacy of diltiazem in the treatment of diffuse oesophageal spasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2979217" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Comparison of calcium channel blocking agents and an anticholinergic agent on oesophageal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10201458" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Different effects of an oral anticholinergic drug on gastroesophageal reflux in upright and supine position in normal, ambulant subjects: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6288509" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3582908" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Oral nifedipine in the treatment of noncardiac chest pain in patients with the nutcracker esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8159194" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Imipramine in patients with chest pain despite normal coronary angiograms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16825932" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Clinical relevance of the nutcracker esophagus: suggested revision of criteria for diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11374670" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Pathophysiology of chest pain in patients with nutcracker esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3549420" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10192608" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16422995" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29274869" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22239853" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Systematic review: the treatment of noncardiac chest pain with antidepressants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25412947" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Systematic review with meta-analysis: selective serotonin reuptake inhibitors for noncardiac chest pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12010875" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10648452" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Effects of sildenafil on esophageal motility of patients with idiopathic achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17883431" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Sildenafil relieves symptoms and normalizes motility in patients with oesophageal spasm: a report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11726856" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Treatment of symptomatic diffuse esophageal spasm by endoscopic injections of botulinum toxin: a prospective study with long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12135012" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25212219" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Botulinum toxin injection for hypercontractile or spastic esophageal motility disorders: may high-resolution manometry help to select cases?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23591282" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Botulinum toxin reduces Dysphagia in patients with nonachalasia primary esophageal motility disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30974039" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Botulinum toxin for the treatment of hypercontractile esophagus: Results of a double-blind randomized sham-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35227779" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Esophageal Motility Disorders: Current Approach to Diagnostics and Therapeutics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27858325" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Is POEM the Answer for Management of Spastic Esophageal Disorders? A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30105290" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Peroral endoscopic myotomy is effective and safe in non-achalasia esophageal motility disorders: an international multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32657960" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Long-term Outcomes of Per-oral Endoscopic Myotomy in Spastic Esophageal Motility Disorders: A Large, Single-Center Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31073769" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Clinical efficacy of per-oral endoscopic myotomy (POEM) for spastic esophageal disorders: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17497756" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Functional results after extended myotomy for diffuse oesophageal spasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35249162" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Clinical presentation and therapeutic outcome of patients with jackhammer esophagus-a multicenter cohort study in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26646704" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Esophageal diverticula are associated with propagating peristalsis: a study utilizing high-resolution manometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27660053" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Do Jackhammer contractions lead to achalasia? A longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16133957" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Does diffuse esophageal spasm progress to achalasia? A prospective cohort study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
